Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Yue Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jilin University, Changchun 130021, China. Hauptthemen laut MEDLINE: Lipid Bilayers, Nanoparticles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
To improve the oral absorption and anticancer efficacy of the BCS-IV drug etoposide (ETO), oral nanocrystal-loaded lipid carriers (Lipo@NCs) were developed in this study by modifying the BCS-IV drug nanocrystal with the lipid bilayer. The ETO-Lipo@NCs were prepared by the thin film hydration high-pressure homogenization method, and the core of positively charged ETO nanocrystals was prepared by the sonoprecipitation-high pressure homogenization method. The optimized ETO-Lipo@NCs were spherical particles with an average particle size of 220.3 ± 14.2 nm and a zeta potential of -9.95 ± 0.81 mV, respectively. The successful coating of a lipid bilayer on the surface of nanocrystals in ETO-Lipo@NCs was confirmed by several characterization methods. Compared to nanocrystals, the release rate and degree of Lipo@NCs in SIF were significantly decreased, indicating that the lipid bilayer can effectively prevent the rapid dissolution of core nanocrystals. ETO-Lipo@NCs demonstrated a significant improvement in the intestinal permeability and absorption of ETO in a single intestinal perfusion experiment. In the cells, ETO-Lipo@NCs showed enhanced cellular uptake and transepithelial transport compared with ETO nanocrystals. Pharmacokinetic analysis indicated that ETO-Lipo@NCs had a longer plasma half-life than ETO solution, and the oral bioavailability of ETO-Lipo@NCs was 1.96- and 10.92-fold higher than that of ETO nanocrystals and ETO coarse crystals, respectively. Moreover, the ETO-Lipo@NCs orally dosed at 10 mg/kg exhibited an excellent inhibitory effect against tumors in a subcutaneous Lewis lung carcinoma (LLC) xenograft model compared with other preparations. These results indicate that the Lipo@NCs formulation has an oral absorption-promoting effect of the BCS-IV drug ETO, which could warrant further application in the oral delivery of other poorly bioavailable drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jilin University, Changchun 130021, China.
- Department of Pharmacy, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Science; Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual A…
- The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130021, China.
- Department of Pharmacy, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, China.
ORCID-Profile: Yue Wang
Zitieren
APA
Wang, Y., Wang, P., Li, H., Han, X., Zhu, H., & Jin, X. (2024). Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00785
Vancouver
Wang Y, Wang P, Li H, Han X, Zhu H, Jin X. Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00785
BibTeX
@article{Wang2024,
author = {Wang, Yue and Wang, Ping and Li, Haiyan and Han, Xiaoran and Zhu, Haibin and Jin, Xiangqun},
title = {Nanocrystal-Loaded Lipid Carriers for Improved Oral Absorption and Anticancer Efficacy of Etoposide: Formulation Development, Transport Mechanism, In Vitro and In Vivo Evaluation},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00785}
}
EUVIMED